With three observations
Granules India announced that its wholly owned foreign subsidiary, Granules Pharmaceuticals Inc., located in Chantilly, Virginia, USA had undergone a Preapproval Inspection (PAI) by the US Food and Drug Administration (USFDA) from 24 to 28 January 2022.
The audit is a PAI for two of its product applications filed from this facility. The USFDA issued three minor observations during the audit conducted at the facility.
Powered by Capital Market – Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
First Published: Mon, January 31 2022. 09:09 IST
Leave a Reply